Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Miocamycin [(2S,3S,4R,6R)-4-acetyloxy-6- [(2R,3S,4R,5R...

Synonyms: Macroral, Miocamen, Miokamycin, Myocamicin, Miocamycine, ...

Couet, W. et al., Couet, W. et al., Couet, W. et al., Couet, W. et al., Couet, W. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on Miokamycin

A statistically significant effect of ponsinomycin on the kinetics of R(+) and S(-)-nicoumalone was not demonstrated [1].
A moderate (+13%) but statistically significant (p less than 0.05) increase of CBZ total area under the curve (AUC), was observed in the presence of ponsinomycin, accompanied by a 26% decrease (p less than 0.01) in the AUC of its metabolite [2].
Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally [3].
These data are consistent with an increase of DHE bioavailability in the presence of ponsinomycin, probably related to a reduction of its first-pass elimination [3].

Associations of Miokamycin with other chemical compounds

The influence of treatment with ponsinomycin, a new macrolide antibiotic, on the pharmacokinetics of cyclosporin A has been studied in 10 renal transplant patients [4].
The influence of ponsinomycin on the pharmacokinetics of theophylline has been studied in 12 young healthy volunteers [5].

References

Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers. Couet, W., Istin, B., Decourt, J.P., Ingrand, I., Girault, J., Fourtillan, J.B. British journal of clinical pharmacology. (1990) [Pubmed]
Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Couet, W., Istin, B., Ingrand, I., Girault, J., Fourtillan, J.B. Therapeutic drug monitoring. (1990) [Pubmed]
Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally. Couet, W., Mathieu, H.P., Fourtillan, J.B. Fundamental & clinical pharmacology. (1991) [Pubmed]
Effect of ponsinomycin on cyclosporin pharmacokinetics. Couet, W., Istin, B., Seniuta, P., Morel, D., Potaux, L., Fourtillan, J.B. Eur. J. Clin. Pharmacol. (1990) [Pubmed]
Lack of effect of ponsinomycin on the plasma pharmacokinetics of theophylline. Couet, W., Ingrand, I., Reigner, B., Girault, J., Bizouard, J., Fourtillan, J.B. Eur. J. Clin. Pharmacol. (1989) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share